| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| Referral date | 01 September 2011 |
| Topic area |
|
| Description |
Scoped within Batch 19 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | Kate Moore |
| Technical Lead: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 5 February 2013 |
NICE have been informed by the manufacturer of ridaforolimus that the Marketing Authorisation application for ridaforolimus with the EMA has been withdrawn. View further information. This appraisal consequently remains suspended and NICE will continue to monitor any developments. |
| 31 May 2012 | The manufacturer of ridaforolimus has informed us that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal. |
For further information on our processes and methods, please see our CHTE processes and methods manual